TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03276481

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral microbiota assessment
Description: Whole mouth microbiota will be assessed by having participants swish in their mouth 10 ml of sterile water for 30 sec and then expectorate in a sterile container. Specimens will be immediately placed on wet ice and transferred to the laboratory for processing or for storage at -80° C until they are ready to be prepared for sequencing.
Study: NCT04751175

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physiologic saline
Description: placebo
Study: NCT03276481

Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive chemical gustometry
Description: Chemical gustometry assessments will be performed by a trained clinician on the study team, including a Registered Dietitian, Physician's Assistant, or Research Nurse. The test solutions and gradients will be formulated in house using sterile water and the following constituents: Sweet taste; 0.05, 0.1, and 0.2 g/ml sucrose, sour taste; 0.05, 0.09, and 0.165 g/ml citric acid, salty taste; 0.016, 0.04, and 0.1 g/ml NaCl and bitter taste; 0.0004, 0.0009, and 0.0024g/ml quinine-HCl. Umami will be tested with MSG at 25, 50, and 75 mM.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of salivary flow
Description: Both stimulated and un-stimulated salivation will be assessed by saliva collection in pre-weighed plastic containers. Participants will be seated with their back at a 90 degree angle and asked to swallow everything in their mouth. They will then be asked not to swallow and spit the accumulated saliva in the plastic container every 30 seconds for two minutes (unstimulated flow). For measurement of stimulated saliva, we will follow the same procedure except that after the initial swallow, participants will have their tongue swabbed twice with a cotton swab dipped in ascorbic acid solution or lemon juice.

Intervention type: BEHAVIORAL
Intervention: Surveys assessing taste disturbances
Description: Surveys will be administered and examine taste disturbances pre and post HCT.
Study: NCT00635583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increased Dairy Consumption
Description: 3 additional servings of dairy (two of which must be milk or yogurt)~* 8 oz milk~* 6 oz yogurt~* 1.5 oz cheese
Study: NCT02468375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron 50mg
Description: 434 OAB patient intake mirabegron 50mg/day for 12 weeks.
Study: NCT04633720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Changes in positive end-expiratory pressure and tidal volume
Description: When the patient is in the supine position 10 minutes after induction of anesthesia, the following 4 mechanical ventilator settings are applied to the patients in order.~Positive end-expiratory pressure 8 cmH2O, tidal volume 8 ml/kg Positive end-expiratory pressure 10 cmH2O, tidal volume 5 ml/kg Positive end-expiratory pressure 10 cmH2O, tidal volume 8 ml/kg Positive end-expiratory pressure 12 cmH2O, tidal volume 5 ml/kg
Study: NCT01132690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa
Description: Taliglucerase alfa for infusion every two weeks for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa
Description: Taliglucerase alfa for infusion every two weeks for 12 months
Study: NCT03322891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Supplement
Description: Participants will receive education about prostate cancer and treatments using models and props during a face-to-face interview. During the interview, participants will also be asked about medical terms and treatments regarding prostate cancer. The interview will last 45 to 60 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Practice Education
Description: Participants will receive traditional standard of care education regarding prostate cancer treatments and side effects provided by their physician.
Study: NCT05446155

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: Diagnostic and prognostic imaging, omics and machine learning methods will be applied

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: Diagnostic and prognostic imaging, omics and machine learning methods will be applied
Study: NCT02334254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban and ticagrel therapy
Description: Antiplatelet therapy are mandatory at least 1 month after bare metal stent implantation, and 6 months after drug-eluting stent implantation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triple antithrombotic regimen with warfarin, asipirin and clopidogrel
Study: NCT00944021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 150 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifafour e-275 mg
Description: 275 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 200 mg
Study: NCT05099588

Intervention type: OTHER
Intervention: Other: observational study
Description: Observational study
Study: NCT05986058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Golden Circle
Description: The original Golden Circle project was deployed in response to the COVID-19 pandemic and the need to implement remote social services in South Korea. Golden Circle had the aim of building a case management model using a healthcare-oriented automation system based on wearable devices (smartwatches and mobile applications). Through innovative system expansions, the goals were to promote healthful CVH and physical function and cultivate self-care management skills in older Korean adults.
Study: NCT04751175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physiologic saline
Description: placebo
Study: NCT06354842

Intervention type: DIAGNOSTIC_TEST
Intervention: pilocarpine iontopheresis
Description: Application of pilocarpine on the skin of the patients/subjects to induce sweat production to analyse sweat sodium concentration via flame photometry

Intervention type: DIAGNOSTIC_TEST
Intervention: pilocarpine iontopheresis
Description: Application of pilocarpine on the skin of the patients/subjects to induce sweat production to analyse sweat sodium concentration via flame photometry

Intervention type: DIAGNOSTIC_TEST
Intervention: pilocarpine iontopheresis
Description: Application of pilocarpine on the skin of the patients/subjects to induce sweat production to analyse sweat sodium concentration via flame photometry

Intervention type: DIAGNOSTIC_TEST
Intervention: pilocarpine iontopheresis
Description: Application of pilocarpine on the skin of the patients/subjects to induce sweat production to analyse sweat sodium concentration via flame photometry

Intervention type: DIAGNOSTIC_TEST
Intervention: pilocarpine iontopheresis
Description: Application of pilocarpine on the skin of the patients/subjects to induce sweat production to analyse sweat sodium concentration via flame photometry
Study: NCT02393144

Intervention type: DRUG
Group type: OTHER
Intervention: Analgesics, Opioid, Meperidine
Description: Administration of meperidine for labor analgesia.

Intervention type: DRUG
Group type: OTHER
Intervention: Labor augmentation, Oxytocin
Description: Oxytocin infusion for augmentation of labor.

Intervention type: DRUG
Group type: OTHER
Intervention: Labor induction, Oxytocin
Description: Oxytocin infusion for induction of labor.

Intervention type: DRUG
Group type: OTHER
Intervention: Cervical ripening, labor induction, Dinoprostone
Description: Administration of dinoprostone pessary for cervical ripening and labor induction.
Study: NCT03186651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TVS
Description: Efficacy of a novel intra-vaginal device for temporary reduction of urine leakage in women suffering from stress urinary incontinence and to evaluate the safety and ease of use.
Study: NCT06354842

Intervention type: DIAGNOSTIC_TEST
Intervention: pilocarpine iontopheresis
Description: Application of pilocarpine on the skin of the patients/subjects to induce sweat production to analyse sweat sodium concentration via flame photometry

Intervention type: DIAGNOSTIC_TEST
Intervention: pilocarpine iontopheresis
Description: Application of pilocarpine on the skin of the patients/subjects to induce sweat production to analyse sweat sodium concentration via flame photometry
Study: NCT01923909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-articular platelet-rich plasma
Description: Intra-articular platelet-rich plasma This involves withdrawal of 10-15cc of patient's blood, which is collected and centrifuged in Rotofix 32 A Centrifuge machine at 1500 cycles/minute for 5 minutes. 3-4cc of the PRP is obtained and injected into the supra patellar pouch using an aseptic technique. The procedure will be performed by the principal investigator, a qualified consultant Orthopedic surgeon. Analgesia will be administered as needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular corticosteroid injections
Description: Patients receiving the IA corticosteroid will be injected 3mL of 0.5% Bupivacaine and 2mL of 80mg Depo Medrol in a 10cc syringe, using an aseptic technique into the supra patellar pouch. After an IA corticosteroid injection, patients are always advised to rest for 24 hours, and weigh bear as little as possible for the following 3 days. The procedure will be performed by a senior resident with several years of experience or a consultant Orthopedic surgeon.
Study: NCT03287154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS stimulations
Description: 20 min, 2mA

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: 20 min, Sham
Study: NCT03720444

Intervention type: OTHER
Intervention: MDT (mechanical diagnosis and therapy) method
Description: The intervention consists of a first session to carry out an assessment, followed by 4 reassessment sessions
Study: NCT04363359

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5ml Quadrivalent influenza vaccine
Description: The inactivated split virion vaccines contained 15 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2, B/Victoria and B/Yamagata strains

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.25ml Quadrivalent influenza vaccine
Description: The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2, B/Victoria and B/Yamagata strains

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 0.25ml Trivalent influenza vaccine(B/V)
Description: The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2 and B/Victoria strains

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 0.25ml Trivalent influenza vaccine(B/Y)
Description: The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2 and B/Yamagata strains
Study: NCT03886129

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Doppler Ultrasound (TCD)
Description: Participants will undergo an assessment of brain blood flow using TCD, with two small ultrasound probes held in place on the temples with a customised headframe. During the assessment, heart rate, breathing and blood pressure will also be monitored using a 3 lead ECG, nasal capnography and Finometer® respectively. The assessment will comprise three recordings. Firstly, participants will sit quietly for 5 minutes. Next, they will be asked to sit quietly for one minute before standing and remaining standing for 5 minutes. Lastly, they will be asked to stand and then complete a squat-stand manoeuvre in time with a computer sequence. A tilt sensor attached to the thigh will measure the efficiency and angle of the squatting motion. The squat-stand manoeuvre will consist of 15 squats and participants will be informed that they should try and complete all 15 squats if possible.
Study: NCT04751175

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline
Description: placebo
Study: NCT00231894

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: pioglitazone 30-45 mg/day

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life style diet group
Description: life style diet education group 1x/week

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Life style diet group
Description: life style diet education group 1x/week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator capsules
Study: NCT01236027

Intervention type: OTHER
Intervention: no intervention
Description: not applicable-no intervention
Study: NCT04181541

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Provider type: Physicians
Description: In this cohort, women will receive second trimester medical abortion care from physicians

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Provider type: Midlevel Providers
Description: In this cohort, women will receive second trimester medical abortion care from midlevel providers.
Study: NCT04110873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antroquinonol Capsule 50mg
Description: patients will receive Antroquinonol 50mg per day (QD) on Day 1 for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antroquinonol Capsule 100mg
Description: patients will receive Antroquinonol 100mg per day (QD) on Day 1 for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: patients will receive placebo per day (QD) on Day 1 for 12 weeks
Study: NCT05181943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simpler diode laser
Description: Non-contacting irradiation for 30 seconds on three intraoral sites repeated four times

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional symptomatic treatment
Description: Conventional treatment using oracure, BBC spray, miconaz three times daily
Study: NCT01471067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m2 by vein on Day -2 only for Fludarabine + Melphalan group.
Study: NCT01125072

Intervention type: OTHER
Intervention: Echocardiography with strain analysis
Description: Clinical routine echocardiogram with additional off line strain analysis
Study: NCT06354842

Intervention type: DIAGNOSTIC_TEST
Intervention: pilocarpine iontopheresis
Description: Application of pilocarpine on the skin of the patients/subjects to induce sweat production to analyse sweat sodium concentration via flame photometry
Study: NCT01061710

Intervention type: DRUG
Intervention: varenicline
Description: Dosage form: tablet 0.5mg, tablet 1mg. The usual adult dosage for oral use is 0.5 mg once daily after eating on Days 1 to 3; 0.5 mg twice daily after eating in the morning and evening on Days 4 to 7, and 1 mg twice daily after eating in the morning and evening on Day 8 and thereafter. The drug should be administered to subjects for 12 weeks.
Study: NCT01287429

Intervention type: OTHER
Intervention: lung and pleural ultrasound
Description: After the initial diagnostic work-out (medical history, physical examination, EKG, arterious blood gas), the emergency physician will classify dyspnoea in cardiogenic or respiratory dyspnoea and write it down in a specific form (clinical form). Immediately after this, lung and pleural ultrasound will be performed: the physician will describe it and evaluate the etiology again (integrated evaluation form). Then a chest X-ray evaluation will be performed for each patient.
Study: NCT02104011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Study: NCT00201773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25 mg orally once per day for 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: given orally at two 200 mg capsules (400 mg) twice per day. Patients assigned to receive 400 mg twice per day should be instructed to take the drug with food.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative studies
Study: NCT04032327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel plus plain bupivacaine
Description: 10 mL of extended release liposomal bupivacaine (Exparel) plus 10 mL of 0.25% plain bupivacaine mixed to be injected vaginally prior to the start of posterior colporrhaphy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 mL of 0.25% plain bupivacaine to be injected vaginally prior to the start of posterior colporrhaphy
Study: NCT03099863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cystoscopic Fluid containing Neosporin G. U. Irrigant
Description: Normal saline cystoscopic fluid containing Neosporin G. U. Irrigant 1mL/1000mL

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cystoscopy
Description: Diagnostic cystoscopy performed during pelvic floor surgery

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cystoscopy
Description: Diagnostic cystoscopy performed during pelvic floor surgery
Study: NCT03937557

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: photofinder levicam
Description: Exam frontal, bilateral Temporal and occipital scalp by photofinder levicam and compare the pros and cons with the data from scalp biopsy.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: photofinder levicam
Description: Exam frontal, bilateral Temporal and occipital scalp by photofinder levicam and compare the pros and cons with the data from scalp biopsy.
Study: NCT01471067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 10 mg/m2 by vein on Days -7 to -4 for Melphalan + Thiotepa + Fludarabine group, or 40 mg on Days -5 to -2 for Fludarabine + Melphalan group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 10 mg/m2 by vein on Days -7 to -4 for Melphalan + Thiotepa + Fludarabine group, or 40 mg on Days -5 to -2 for Fludarabine + Melphalan group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth twice a day from Days -3 to +100 in the absence of Graft vs Host Disease (GvHD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth twice a day from Days -3 to +100 in the absence of Graft vs Host Disease (GvHD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on Day -2 and tapered around Day +180 if no Graft vs Host Disease (GvHD) is present.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on Day -2 and tapered around Day +180 if no Graft vs Host Disease (GvHD) is present.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord Blood Infusion
Description: Cord blood infusion on Day 0. Each participant will receive cells from one unexpanded cord blood sample plus cells from a second cord blood sample that has undergone fucosylation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord Blood Infusion
Description: Cord blood infusion on Day 0. Each participant will receive cells from one unexpanded cord blood sample plus cells from a second cord blood sample that has undergone fucosylation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 by vein on Day -10 for B cell malignancy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: 1.25 mg/Kg by vein on Day -4.~1.75 mg/Kg by vein on Day -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: 1.25 mg/Kg by vein on Day -4.~1.75 mg/Kg by vein on Day -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan per standard of care, test dose either as an outpatient prior to admission or as an inpatient on Day -9. Busulfan pharmacokinetics performed with test dose and the first dose on Day -7 per standard of care. Doses of Days -5 and -4 subsequently adjusted to target an AUC of 4,000 microMol.min-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: 30 mg/m\^2 IV Day -7 to Day -4;

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: 2 Gy in AM of Day -3.
Study: NCT03099863

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cystoscopic Fluid/Placebo
Description: Normal saline cystoscopic fluid
Study: NCT04065256

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized music
Description: Personalized music intervention will be conducted by research nurse independently. Firstly, the music preference will be confirmed by using predesigned music list. After confirming the music preference, participants will receive a music session for forty minutes through headphone and MP3 player.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized music plus earplug
Description: Personalized music intervention will be conducted by research nurse independently. Firstly, the music preference will be confirmed by using predesigned music list. After confirming the music preference, participants will receive a music session for forty minutes through headphone and MP3 player. In addition, participants will be worn earplug during night time sleep for decreasing the noise until next morning.
Study: NCT02427217

Intervention type: BIOLOGICAL
Intervention: FCH
Description: FCH is a heat-treated, lyophilized fibrinogen (coagulation factor I) powder made from pooled human plasma. FCH is administered as an IV infusion.
Study: NCT01491932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Description: AFQ056 will be supplied as oral capsules.
Study: NCT00026403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT00003937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery